Biologics Cell & Gene Small Molecules Capsules & Health Ingredients Corporate
Media Advisory New Technologies Partnerships Sustainability New Products General Acquisitions Ad hoc Financials
2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
English Deutsch French
Media AdvisoryX
EnglishX
Showing 1‐20 of 41
Cell & Gene
11 Mar 2025
Exogenus Therapeutics Chooses Lonza to Develop a GMP-Compliant Process to Manufacture Exo-101, its Lead Exosome-Based Candidate
Lonza to develop a GMP-compliant process for Exo-101 manufacturing from its Siena (IT) site Exo-101 has shown safety and efficacy in multiple pre-clinical trials, and...
Capsules & Health Ingredients
06 Mar 2025
Lonza Capsules & Health Ingredients Establishes Center of Applied Sustainability
As part of Lonza Capsules & Health Ingredients’ (CHI) continued focus on sustainability, a new Center of  Applied Sustainability has been established to accelerate...
Small Molecules
13 Jan 2025
Iconovo and Lonza to Collaborate on the Formulation Development of an Intranasal Biologic
Lonza to develop spray-dried formulations for an intranasally-delivered biologic for Iconovo at its Center of Excellence for bioavailability enhancement and inhaled delivery in...
Capsules & Health Ingredients
19 Dec 2024
Lonza Capsules & Health Ingredients Expands Capsule Manufacturing Capacity in India and China
New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari (IN) and Suzhou (CN), highlighting the long-term strategic commitment to...
Capsules & Health Ingredients
03 Dec 2024
Lonza Launches Tailored Offering for Smart Capsules Companies Developing Oral Delivery Solutions for Biologic Drugs
Tailored offering for companies developing smart capsules includes bespoke targeted drug delivery solutions and customized capsule designs for oral biologic drugs Service...
Biologics
20 Nov 2024
​​Lonza Announces First GMP Batch Completion at ​Next-Generation Mammalian Manufacturing Facility in Portsmouth (US)
First GMP batch released at Lonza’s next-generation mammalian manufacturing facility in Portsmouth (US)   State-of-the-art technology supports Lonza’s next-generation mammalian...
Biologics
04 Nov 2024
Lonza’s Synaffix Collaborates with BigHat Biosciences on the Development of a Machine Learning-Designed ADC
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies Collaboration underscores Lonza’s commitment to helping...
Biologics
15 Oct 2024
Lonza Completes Expansion of New Drug Product Services Facility in Basel (CH)
Expansion adds a new facility to Lonza’s Drug Product Services (DPS) footprint, supporting clinical and commercial projects through additional quality control (QC) and...
Cell & Gene
26 Sep 2024
Lonza Walkersville Commences Expansion of Endotoxin Assay Production Facility
Lonza Walkersville is investing in an expansion of its endotoxin assay production facility The upgraded facility will incorporate sustainable technologies and streamline...
Biologics
26 Sep 2024
Acumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer’s Disease
Agreement builds upon a successful collaboration supporting the manufacture of sabirnetug (ACU193) drug substance (DS) for clinical studies in Alzheimer’s disease Extension to...
Capsules & Health Ingredients
19 Sep 2024
Lonza Launches Innovaform™ Accelerator, the New Innovation and Formulation Center in Colmar (FR)
The new facility will serve as a Center of Excellence for co-innovation with pharmaceutical customers on formulation and encapsulation innovation projects The facility includes...
Biologics
05 Sep 2024
​​Lonza Completes Expansion of Microbial Manufacturing Facility in Visp (CH) ​
Expansion adds manufacturing capacity for clinical and commercial supply of microbially-produced biologics The facility is now GMP-qualified for manufacturing...
Biologics
15 Aug 2024
UK Government Supports Lonza’s Expansion Plans
Lonza has purchased a plot in Thames Valley Park, with a view to relocating and expanding its primary UK-based Biologics site over the next decade This proposed new site would...
Cell & Gene
13 Aug 2024
Champalimaud Foundation Adopts Lonza’s MODA-ES® Platform to Streamline Cell Therapy Manufacturing
MODA-ES® Platform, a next-generation manufacturing execution system for cell and gene therapies, facilitates a cost-effective transition to electronic record-keeping By...
Small Molecules
06 Aug 2024
Lonza Upgrades Clinical Manufacturing Services at Bend (US) Site to Include Bottling and Labeling Capabilities
Lonza Bend (US) upgrades capabilities in early phase clinical manufacturing services with the addition of bottling and labeling equipment New equipment to support bottling of...
Capsules & Health Ingredients
20 Jun 2024
Lonza Launches Enprotect® Size 9 Capsule to Accelerate Pre-Clinical Development of Acid-Sensitive Active Pharmaceutical Ingredients
Lonza launches Capsugel® Enprotect® size 9 capsule to support the evaluation of candidate drugs New size 9 capsule enables pre-clinical testing in rodents, which accelerates...
Small Molecules
29 Apr 2024
Lonza Launches AI-Enabled Route Scouting Service to Accelerate Small Molecule Development
New advanced technology-enabled offering aims to streamline synthetic route identification for novel active pharmaceutical ingredients (APIs) The AI-driven route design...
Corporate
17 Apr 2024
Lonza Signs Multiple Renewable Energy Certificate Agreements in the United States
Lonza signs three Renewable Energy Certificate (REC) purchase agreements in the United States (US), supporting the commissioning of additional renewable energy projects
Cell & Gene
09 Apr 2024
NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics
NeuroSense will leverage its extensive experience in biomarker utilization to advance early diagnosis and treatment in the neurodegeneration field Lonza to develop, optimize,...
Biologics
04 Apr 2024
Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease
Lonza to manufacture Acumen’s monoclonal antibody, sabirnetug (ACU193), for clinical development and commercialization, if approved Sabirnetug is the first monoclonal antibody...
1 2 3 >